KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Assets (2016 - 2026)

Fulgent Genetics' Assets history spans 12 years, with the latest figure at $1.2 billion for Q1 2026.

  • On a quarterly basis, Assets fell 4.09% to $1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 billion, a 4.09% decrease, with the full-year FY2025 number at $1.2 billion, down 0.53% from a year prior.
  • Assets hit $1.2 billion in Q1 2026 for Fulgent Genetics, down from $1.2 billion in the prior quarter.
  • Over the last five years, Assets for FLGT hit a ceiling of $1.5 billion in Q1 2022 and a floor of $93.2 million in Q4 2022.
  • Historically, Assets has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
  • Biggest five-year swings in Assets: tumbled 92.71% in 2022 and later soared 1225.0% in 2023.
  • Tracing FLGT's Assets over 5 years: stood at $93.2 million in 2022, then soared by 1225.0% to $1.2 billion in 2023, then dropped by 1.24% to $1.2 billion in 2024, then decreased by 0.53% to $1.2 billion in 2025, then fell by 4.71% to $1.2 billion in 2026.
  • Business Quant data shows Assets for FLGT at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.